PMID- 37727917
OWN - NLM
STAT- MEDLINE
DCOM- 20230921
LR  - 20231002
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 64
IP  - 10
DP  - 2023 Oct
TI  - Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic 
      Malignancies.
PG  - 587-592
LID - 10.3349/ymj.2023.0063 [doi]
AB  - PURPOSE: We investigated the treatment outcomes of immune checkpoint inhibitor 
      (ICI) rechallenge in patients with recurrent gynecologic cancers. MATERIALS AND 
      METHODS: We retrospectively reviewed the medical records of 20 patients who 
      underwent rechallenge with PD-1 inhibitors for recurrent gynecologic cancers at 
      two tertiary centers between January 2018 and September 2022. RESULTS: The median 
      age of the patients was 56 years (range, 35-79). Seven (35%), 1 (5%), 11 (55%), 
      and 1 (5%) patients presented with cervical, vulvar, ovarian, and endometrial 
      cancers, respectively. Sixteen (80%) patients received pembrolizumab and 4 (20%) 
      received nivolumab at first treatment. Eight (40%) and 12 (60%) patients received 
      pembrolizumab and nivolumab, respectively, at second treatment. At initial ICI 
      treatment, 1 (5%) and 4 (20%) cases of a complete response (CR) and a partial 
      response (PR) were observed, respectively, with a median progression-free 
      survival (PFS) of 2.8 months (range, 1.4-49.6). Reasons for first ICI 
      discontinuation were disease progression (n=16), severe adverse events (AEs) 
      (n=2), and treatment withdrawal (n=2). During second ICI treatment, 1 (5%) 
      patient achieved CR, 2 (10%) showed PR, and 5 (25%) experienced stable disease. 
      The median PFS to second ICI was 1.8 months (range, 0.4-10.4). The median overall 
      survival was 21.3 months (range, 10.1-52.7). Neither patient who discontinued ICI 
      treatment due to AEs experienced AE relapse during second ICI treatment. 
      CONCLUSION: These results suggest that responses to ICI rechallenge are not as 
      intolerable as responses to previous ICI. Clinicians should carefully consider 
      rechallenge with PD-1 inhibitors outside of clinical trials until there are 
      sufficient data to routinely support this practice.
CI  - (c) Copyright: Yonsei University College of Medicine 2023.
FAU - Kim, Migang
AU  - Kim M
AUID- ORCID: 0000-0001-6950-0693
AD  - Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA 
      University School of Medicine, Seongnam, Korea.
FAU - Chang, Chi-Son
AU  - Chang CS
AUID- ORCID: 0000-0002-0169-2008
AD  - Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
FAU - Choi, Min Chul
AU  - Choi MC
AUID- ORCID: 0000-0003-4509-6731
AD  - Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA 
      University School of Medicine, Seongnam, Korea. oursk79@cha.ac.kr.
FAU - Lee, Jeong-Won
AU  - Lee JW
AUID- ORCID: 0000-0002-6110-4909
AD  - Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea. garden.lee@samsung.com.
FAU - Park, Hyun
AU  - Park H
AUID- ORCID: 0000-0002-7825-9165
AD  - Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA 
      University School of Medicine, Seongnam, Korea.
FAU - Joo, Won Duk
AU  - Joo WD
AUID- ORCID: 0000-0003-4637-6946
AD  - Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA 
      University School of Medicine, Seongnam, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Humans
MH  - Female
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - *Genital Neoplasms, Female
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Nivolumab/therapeutic use
MH  - Retrospective Studies
MH  - Chronic Disease
MH  - Recurrence
PMC - PMC10522879
OTO - NOTNLM
OT  - Gynecologic malignancy
OT  - immune checkpoint inhibitor
OT  - rechallenge
OT  - recurrence
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2023/09/20 06:42
MHDA- 2023/09/21 06:42
PMCR- 2023/10/01
CRDT- 2023/09/20 04:03
PHST- 2023/03/30 00:00 [received]
PHST- 2023/06/30 00:00 [revised]
PHST- 2023/07/26 00:00 [accepted]
PHST- 2023/09/21 06:42 [medline]
PHST- 2023/09/20 06:42 [pubmed]
PHST- 2023/09/20 04:03 [entrez]
PHST- 2023/10/01 00:00 [pmc-release]
AID - 64.587 [pii]
AID - 10.3349/ymj.2023.0063 [doi]
PST - ppublish
SO  - Yonsei Med J. 2023 Oct;64(10):587-592. doi: 10.3349/ymj.2023.0063.